Study Evaluating rFIX; BeneFIX in Severe Hemophilia B
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To characterize the safety and efficacy of rFIX in children less than 6 years of age with severe hemophilia B in the setting of acute bleeding episodes, prophylaxis, and/or surgery.
This study will provide an opportunity for systematic observation of treatment with rFIX in children less than 6 years of age regardless of prior FIX treatment. Younger patients exhibit a different pharmacokinetic profile and therefore may respond differently to rFIX infusions when compared with older children and adults. This evaluation will provide data from which recommendations can be made regarding rFIX dosing and treatment of these patients. Surveillance for certain observations that have been made in patients treated with rFIX in the clinical and postmarketing setting will be performed, including inhibitor development, thrombogenicity, FIX recovery/lack of effect, allergic-type manifestations, and RBC agglutination. Comparisons will be derived from published reports and communications describing experience with other FIX products and protein therapeutics in general.
| Condition | Intervention | Phase |
|---|---|---|
|
Hemophilia B |
Drug: BeneFIX |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | An Open-Label, Single-Arm, Safety and Efficacy Study of Recombinant Human Factor IX (rFIX; BeneFIX®) in Children Less Than 6 Years of Age With Severe Hemophilia B |
- To characterize the safety and efficacy of rFIX in children less than 6 years of age with severe hemophilia B in the setting of acute bleeding episodes, prophylaxis, and/or surgery.
- To measure the incremental recovery of rFIX in children following a 75-IU/kg bolus infusion.
| Estimated Enrollment: | 20 |
| Study Start Date: | September 2002 |
| Study Completion Date: | November 2007 |
Eligibility| Ages Eligible for Study: | up to 5 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Severe hemophilia B
- Less than 5 years of age
- In the investigator's judgment, the patient and/or caregiver will be compliant to study procedures
Exclusion Criteria:
- A currently detectable FIX inhibitor. A family history of inhibitors will not exclude the patient.
- Impaired liver function
- Impaired renal function
Contacts and Locations| United States, Colorado | |
| Aurora, Colorado, United States, 80262 | |
| United States, Michigan | |
| Detroit, Michigan, United States, 48201 | |
| United States, New Jersey | |
| New Brunswick, New Jersey, United States, 08903 | |
| United States, North Carolina | |
| Chapel Hill, North Carolina, United States, 27599-7220 | |
| United States, Ohio | |
| Dayton, Ohio, United States, 45404 | |
| United States, Texas | |
| Houston, Texas, United States, 77030 | |
| Study Director: | Medical Monitor, MD | Wyeth is now a wholly owned subsidiary of Pfizer |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00037557 History of Changes |
| Other Study ID Numbers: | 3090A1-301 |
| Study First Received: | May 17, 2002 |
| Last Updated: | December 18, 2007 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:
|
Hemophilia B |
Additional relevant MeSH terms:
|
Hemophilia B Hemophilia A Blood Coagulation Disorders, Inherited Blood Coagulation Disorders Hematologic Diseases |
Coagulation Protein Disorders Hemorrhagic Disorders Genetic Diseases, Inborn Genetic Diseases, X-Linked |
ClinicalTrials.gov processed this record on May 22, 2013